Aberrantly expressed piRNAs, genetically associated piRNAs and their relationship with cancer risk and severity are provided. Compositions and methods of using piRNA for treating cancer are provided. Methods of diagnosing subjects and determining the efficacy of active agents for treating cancer are also provided. Methods of correlating variant piRNA to cancer are also disclosed.